about
Impact on the Quality of Life of an Educational Program for the Prevention of Work-Related Musculoskeletal Disorders: a randomized controlled trialLow- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.Raised serum S100B protein levels in neuropsychiatric lupus.Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis.Effect of inflammatory activity and glucocorticoid [corrected] use on nutritional variables in patients with juvenile idiopathic arthritis.Fast Cicatrization of Extensive Livedoid Vasculopathy Ulcers under Treatment with Sildenafil.A study of the association between epistaxis and the severity of hypertension.A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al.Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al.Intraorbital polyacrylamide gel injection for the treatment of anophthalmic enophthalmos.Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia - A controlled cross-sectional study.Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.Capillary loss on nailfold capillary microscopy is associated with mortality in systemic sclerosis.Comments on Mignot et al.: bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.How useful is PET/CT in the evaluation of fever/inflammation of unknown origin? Comment on the article by Schönau et al.Ultrasound resistive index, power Doppler, and clinical parameters in established rheumatoid arthritis.[Prevalence of smoking and associated factors in a metropolitan area in the southern region of Brazil]Glu298Asp eNOS polymorphism is not associated with SLE.Antisynthetase syndrome after acute massive inhalation of wood and paint dust.Assessment of nailfold capillaroscopy in systemic sclerosis by different optical magnification methods.TCRBV20S1 and TCRBV3S1 gene segment polymorphisms in systemic sclerosis.The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients.Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis.Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis.Mounting Evidence Indicates That Escalating Doses of Allopurinol Are Unnecessary for Cardiovascular Protection: Comment on the Article by Coburn et alFRI0371 Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosisOP0269 Effect of xanthine oxidase inhibitors on the incidence of cardiovascular events: a systematic review and meta-analysis of randomised controlled trialsAbsence of Association of Joint Tenderness and High-Resolution Ultrasound Findings in Established Rheumatoid ArthritisUltrasound power Doppler synovitis is associated with plasma IL-6 in established rheumatoid arthritisOP0036 Comparison of Low- and High-Dose Rituximab for the Treatment of Rheumatoid Arthritis: An Updated Systematic Review and Meta-AnalysisReplyFRI0494 Long-Term Effectiveness and Safety of Cyclophosphamide in Systemic Sclerosis Lung DiseaseCharacteristics of NK cell activity in patients with systemic sclerosisCaracterísticas de atividade das células natural killer em pacientes com esclerose sistêmicaInterleukin-10 Gene Promoter and NFKB1 Promoter Insertion/Deletion Polymorphisms in Systemic SclerosisLast observation carried forward approach threatens the validity of intent-to-treat analysis in fibromyalgia trials: Comment on the article by Arnold et alOne-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab
P50
Q28386157-95EC589E-2CAF-4F52-8272-85623E8B8E25Q34975404-7810E860-333D-460A-9021-D0DB4DEEC48BQ35637257-145A1568-F30A-46D9-8500-E5A44003514EQ35662575-949F7C16-A7A2-4466-B4B4-DC7F47C6A602Q36230610-269AEB00-2FD7-4AD3-8B2E-94851F3B214CQ36411261-736690E2-6532-4AC1-8C52-DCC547E32F9CQ37654012-D5BA9EC0-9B47-4D66-865C-95D5CADBD637Q38550119-6022C360-4A4D-4FDF-B9CA-2053E4B4B020Q42992767-A2A58A59-9379-4BB5-8B78-96CEC4252019Q45765360-2EB48C72-902E-462C-B312-520EF2586FA9Q47335927-256A2D3E-2A30-491F-8773-0831DD72FFAEQ47743403-9257A759-1A5A-4C7C-B758-451C96477162Q47867451-640AD86C-6E97-44F2-8B4E-3496050DE445Q48212601-28B7396C-713B-4EB7-A7EA-2C797730991EQ48226426-6BF51916-F589-4B78-84F4-23F2A2FEFD74Q48255711-12C39C73-563A-4CD5-A560-A628B2B38238Q49584618-780C0EFD-25AE-4504-A124-F605249F2B9DQ50095763-AB2D1B34-B68F-46F1-97DC-BB5EFAF39842Q51000320-2BA948D6-A16A-4F34-85E2-675C06B65ECAQ51048933-05DCFDA2-D72B-44D4-99D3-CB15D1C6F088Q51752524-36A7D515-A26F-4CA4-9F23-26E8A0B23941Q52984502-2E6E8A4C-CA9D-4E8F-8263-1B57141AB033Q53132181-E632921A-16A5-4347-A96A-F093A44788E9Q53484080-E583EAD7-64C9-4F66-8FCF-957D855912D3Q53519868-2FAE1A68-C431-4D6F-B4EF-002665DC6341Q54302281-1B70E25D-434E-4069-8F2F-F4F27C7CD31CQ54445962-71BC7617-5096-4161-B617-7BCF59B2196AQ57987416-B2CA702B-E7CB-4EFB-AA21-D6C24CD4A551Q57987423-A8C3A366-4ABF-47E0-9534-17E6C7C4ED20Q57987425-D6D6B699-99F9-457C-9334-63E53A5C7801Q57987429-351A0BE6-AE80-4E42-9466-E07982A3F3DBQ57987436-4DDE3570-9813-40C0-9FDB-6E2612B3F900Q57987439-C0295202-0DE3-4249-830D-8807A0334155Q57987446-5FBDA84B-FE1E-41C9-9B48-D8C103D5C062Q57987450-40FBF3B8-C3B3-4CD7-9258-335ABD2D3C82Q57987453-7319A739-C076-46B9-A25A-B025FD0FD198Q57987457-D2EC0926-A7A6-465C-AF01-0FC7A956030EQ57987460-6D4C28D8-ADC4-4683-8DA5-DE971795C2A0Q57987463-6C9F11F2-5703-4134-BE72-07B77A221332Q57987464-E5DB80D0-FF0B-479D-A86C-EFF41018BBFF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Markus Bredemeier
@ast
Markus Bredemeier
@en
Markus Bredemeier
@es
Markus Bredemeier
@nl
Markus Bredemeier
@sl
type
label
Markus Bredemeier
@ast
Markus Bredemeier
@en
Markus Bredemeier
@es
Markus Bredemeier
@nl
Markus Bredemeier
@sl
prefLabel
Markus Bredemeier
@ast
Markus Bredemeier
@en
Markus Bredemeier
@es
Markus Bredemeier
@nl
Markus Bredemeier
@sl
P1053
D-3851-2016
P106
P21
P2798
P31
P3829
P496
0000-0002-7911-593X
P569
2000-01-01T00:00:00Z